Prospective evaluation of bone mineral density among middle-aged HIV-infected and uninfected women: Association between methadone use and bone loss

Maturitas

Volumn 70, Issue 3, 2011, Pages 295-301

  Sharma, Anjali ^a   Cohen, Hillel W ^b   Freeman, Ruth ^b   Santoro, Nanette ^c   Schoenbaum, Ellie E ^b  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

Bone mineral density; HIV; Osteopenia; Osteoporosis; Women

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; METHADONE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AGE DISTRIBUTION; BODY MASS; BONE DENSITY; CD4+ T LYMPHOCYTE; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; HEPATITIS C; HIP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LUMBAR SPINE; MAJOR CLINICAL STUDY; MIDDLE AGED; MIXED INFECTION; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE; PROSPECTIVE STUDY; REVIEW; RISK FACTOR; SEROLOGY; SMOKING;

HEPATITIS C VIRUS;

EID: 80054090005     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2011.08.003     Document Type: Article

References (30)

1. S.E. Dolan, J.S. Huang, K.M. Killilea, M.P. Sullivan, N. Aliabadi, and S. Grinspoon Reduced bone mineral density in HIV-infected women AIDS 18 2004 475 483 (Pubitemid 38365875)
2. M. Yin, J. Dobkin, and K. Brudney Bone mass and mineral metabolism in HIV+ postmenopausal women Osteoporos Int 16 2005 1345 1352 (Pubitemid 41534646)
3. J. Teichmann, E. Stephan, and U. Lange Osteopenia in HIV-infected women prior to highly active antiretroviral therapy J Infect 46 2003 221 227 (Pubitemid 36758180)
4. S.E. Dolan, J.R. Kanter, and S. Grinspoon Longitudinal analysis of bone density in human immunodeficiency virus-infected women J Clin Endocrinol Metab 91 8 2006 2938 2945 (Pubitemid 44271739)
5. M.T. Yin, D. Lu, and S. Cremers Short-term bone loss in HIV-infected premenopausal women J Acquir Immune Defic Syndr 53 February (2) 2010 202 208
6. S.A. Miller, N. Santoro, and Y. Lo Menopause symptoms in HIV-infected and drug-using women Menopause 12 2005 348 356 (Pubitemid 40664218)
7. World Health Organization Research on the menopause in the 1990s: report of a WHO scientific working group 1996 WHO Geneva, Switzerland WHO Technical Report Series No. 866
8. D.G. Mayfield, G. McCleod, and Y.D. He The CAGE questionnaire: validation of a new alcoholism screening instrument Am J Psychiatry 131 1974 1121 1123
9. L.S. Radloff The CES-D scale: a self-report depression scale for research in the general population Appl Psychol Meas 1 1977 385 401
10. D.S. Metzger, B. Koblin, and C. Turner Randomized controlled trial of audio computer-assisted self-interviewing: utility and acceptability in longitudinal studies, HIVNET Vaccine Preparedness Study Protocol Team Am J Epidemiol 152 2000 99 106 (Pubitemid 30463656)
11. World Health Organization Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of WHO study group World Health Org Tech Rep Ser 843 1994 1 129
12. J.H. Arnsten, R. Freeman, A.A. Howard, M. Floris-Moore, N. Santoro, and E.E. Schoenbaum HIV infection and bone mineral density in middle-aged women Clin Infect Dis 42 2006 1014 1020
13. D. Nolan, R. Upton, and E. McKinnon Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir AIDS 15 2001 1275 1280 (Pubitemid 32592360)
14. P. Tebas, W.G. Powderly, and S. Claxton Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy AIDS 14 2000 F63 F76
15. J. Fernandez-Rivera, R. Garcia, and F. Lozano Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients HIV Clin Trials 4 5 2003 337 346 (Pubitemid 37304437)
16. K. Mondy, K. Yarasheski, and W.G. Powderly Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals Clin Infect Dis 36 2003 482 490 (Pubitemid 36241317)
17. D.L. Jacobson, D. Spiegelman, T.K. Knox, and I.B. Wilson Evolution and predictors of change in total bone mineral density over time in HIV-infected men and women in the nutrition for healthy living study J Acquir Immune Defic Syndr 49 November (3) 2008 298 308
18. B. Grund, G. Peng, and C.L. Gibert INSIGHT SMART Body Composition Substudy group. Continuous antiretroviral therapy decreases bone mineral density AIDS 23 July (12) 2009 1519 1529
19. T.T. Brown, G.A. McComsey, M.S. King, R.B. Qaqish, B.M. Bernstein, and B.A. da Silva Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen J Acquir Immune Defic Syndr 51 August (5) 2009 554 561
20. I. Cassetti, J.V. Madruga, and J.M. Suleiman The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naïve HIV-1-infected patients HIV Clin Trials 8 May-June (3) 2007 164 172 (Pubitemid 47121761)
21. C. Duvivier, S. Kolta, and L. Assoumou ANRS 121 Hippocampe study group, Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients AIDS 23 April (7) 2009 817 824
22. J.E. Gallant, S. Staszewski, and A.L. Pozniak Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial JAMA 292 2 2004 Jul 14 191 201 (Pubitemid 38917996)
23. M.G. van Vonderen, P. Lips, and M.A. van Agtmael First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir AIDS 23 July (11) 2009 1367 1376
24. J.H. Arnsten, R. Freeman, A.A. Howard, M. Floris-Moore, Y. Lo, and R.S. Klein Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection AIDS 21 March (5) 2007 617 623
25. O.B. Cooper, T.T. Brown, and A.S. Dobs Opiate drug use: a potential contributor to the endocrine and metabolic complications in human immunodeficiency virus disease Clin Infect Dis 37 2 Suppl. 2003 S132 S136
26. M. Kinjo, S. Setoguchi, S. Schneeweiss, and D.H. Solomon Bone mineral density in subjects using central nervous system-active medications Am J Med 118 2005 1414.e7 1414.e12
27. T.W. Kim, D.P. Alford, A. Malabanan, M.F. Holick, and J.H. Samet Low bone density in patients receiving methadone maintenance treatment Drug Alcohol Depend 85 December (3) 2006 258 262 [Epub 2006 July 21] (Pubitemid 44666285)
28. M. Pedrazzoni, P.P. Vescovi, and L. Maninetti Effects of chronic heroin abuse on bone and mineral metabolism Acta Endocrinol 129 1993 42 45 (Pubitemid 23225790)
29. V.A. Triant, T.T. Brown, H. Lee, and S.K. Grinspoon Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system J Clin Endocrinol Metab 93 September (9) 2008 3499 3504
30. B. Grund, G. Peng, and C.L. Gibert INSIGHT SMART Body Composition Substudy group, Continuous antiretroviral therapy decreases bone mineral density AIDS 23 July (12) 2009 1519 1529